[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Kim JB, Choi JH, Kim JH, Park HJ, Lee JS, Joh OJ, Song KY: A case of primary cutaneous mucinous carcinoma with neuroendocrine differentiation. Ann Dermatol; 2010 Nov;22(4):472-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary cutaneous mucinous carcinoma with neuroendocrine differentiation.
  • Primary cutaneous mucinous carcinoma is a rare malignant tumor that originates from the deepest portion of the eccrine sweat duct.
  • It is difficult to differentiate this tumor histologically from metastatic adenocarcinoma.
  • We report a primary cutaneous mucinous carcinoma with neuroendocrine differentiation on the right cheek of a 63-year-old man.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21165225.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2991732
  • [Keywords] NOTNLM ; Cutaneous mucinous carcinoma / Eccrine sweat duct / Metastatic adenocarcinoma / Neuroendocrine differentiation
  •  go-up   go-down


2. al Saudi N, Maartense E, Scherpenisse J, van Leeuwen AW: Watery diarrhoea: an unusual manifestation of breast cancer. Neth J Med; 2007 Dec;65(11):448-51
MedlinePlus Health Information. consumer health - Diarrhea.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Somatostatin-receptor scintigraphy revealed a hot spot in the left thoracic wall and subsequently, breast adenocarcinoma with neuroendocrine differentiation was diagnosed.
  • [MeSH-minor] Aged, 80 and over. Gastrins. Humans. Male. Neuroendocrine Tumors / complications. Neuroendocrine Tumors / pathology. Pancreatic Polypeptide

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079568.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Gastrins; 59763-91-6 / Pancreatic Polypeptide
  •  go-up   go-down


3. Wang KL, Yang Q, Cleary KR, Swisher SG, Correa AM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT: The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer; 2006 Oct 1;107(7):1467-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation.
  • BACKGROUND: Esophageal and esophagogastric junction (EGJ) adenocarcinomas frequently have neuroendocrine (NE) differentiation, but the significance of NE differentiation in patients who have undergone preoperative chemoradiation and resection remains unclear.
  • METHODS: The authors evaluated the presence of NE differentiation in esophageal and EGJ adenocarcinomas by immunohistochemistry for chromogranin A and synaptophysin and evaluated the clinical significance of NE differentiation in 83 patients (10 patients who had a complete tumor response and 73 patients who had residual tumor in resection specimens) who received preoperative chemoradiation.
  • RESULTS: Of 73 patients who had residual tumor after preoperative treatment, 52% showed NE differentiation.
  • The proportion of tumor cells with NE differentiation had increased from 6% +/- 18% in pretreatment biopsy specimens to 47% +/- 42% (P = .00003) in posttreatment resection specimens in 30 patients who had paired pretreatment biopsy and resection specimens available.
  • Among patients who had residual tumor after preoperative chemoradiation, disease-free survival (P = .03) and overall survival (P = .045) were significantly better in patients who had residual tumor without NE differentiation than in patients who had residual tumor with NE differentiation.
  • In multivariate analysis, the presence of NE differentiation in residual tumor was a prognostic factor for worse disease-free survival (P = .02) independent of pathologic stage and extent of residual tumor.
  • CONCLUSIONS: The results from this study suggested that tumor cells with NE differentiation were more resistant to neoadjuvant chemoradiation in patients with esophageal and EGJ adenocarcinomas.
  • The presence of NE differentiation in residual tumor was associated with poor survival after preoperative neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Neoadjuvant Therapy. Neuroendocrine Tumors / pathology
  • [MeSH-minor] Aged. Cell Differentiation. Chromogranin A. Chromogranins / analysis. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Preoperative Care. Prognosis. Synaptophysin / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955509.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 0 / Synaptophysin
  •  go-up   go-down


Advertisement
4. Hennessy BT, Gilcrease MZ, Kim E, Gonzalez-Angulo AM: Breast carcinoma with neuroendocrine differentiation and myocardial metastases. Clin Breast Cancer; 2007 Dec;7(11):892-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma with neuroendocrine differentiation and myocardial metastases.
  • A 63-year-old Japanese woman was diagnosed with metastatic well-differentiated neuroendocrine carcinoma presenting as a perianal mass without an obvious primary site.
  • Two years later, she presented with a breast mass determined on histologic examination to be the primary neuroendocrine carcinoma.
  • The tumor was weakly positive for estrogen receptor and clearly originated in multifocal ductal carcinoma in situ.
  • Most studies report a relatively poor prognosis and limited treatment responsiveness for neuroendocrine breast carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Neuroendocrine / secondary. Heart Neoplasms / secondary. Neoplasms, Unknown Primary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269781.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Segawa N, Inamoto T, Ibuki N, Mizutani Y, Azuma H, Tsuji M, Katsuoka Y: [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report]. Hinyokika Kiyo; 2010 Jan;56(1):49-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report].
  • A case of neuroendocrine (NE) differentiated prostate cancer is reported herein, which was progressed with NE differentiation during hormonal treatment in adenocarcinoma of the prostate.
  • A prostate biopsy was performed and histological examinations indicated poorly differentiated adenocarcinoma with a Gleason score of 5 + 4 = 9.
  • Immunohistochemical examination of a re-biopsy specimen revealed a neuroendocrine carcinoma.
  • His condition worsened rapidly and he died at 8 months after definite diagnosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Agents, Hormonal / therapeutic use. Leuprolide / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Cell Differentiation. Humans. Male. Phosphopyruvate Hydratase / analysis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104011.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; EC 3.4.21.77 / Prostate-Specific Antigen; EC 4.2.1.11 / Phosphopyruvate Hydratase; EFY6W0M8TG / Leuprolide
  • [Number-of-references] 26
  •  go-up   go-down


6. Ionescu DN, Treaba D, Gilks CB, Leung S, Renouf D, Laskin J, Wood-Baker R, Gown AM: Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance. Am J Surg Pathol; 2007 Jan;31(1):26-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance.
  • The existence of non-small cell lung carcinoma with neuroendocrine differentiation as a distinct entity and its relevance for prognostic and treatment purposes is controversial.
  • This study assesses the frequency and biologic and prognostic significance of neuroendocrine (NE) expression of synaptophysin (SNP), chromogranin (Ch), and neural cell adhesion molecule (N-CAM) using tissue microarray (TMA) and immunohistochemistry.
  • Hematoxylin and eosin-stained sections were subclassified as: 243 adenocarcinoma (ACA), 272 squamous cell carcinoma (SCC), 35 large cell carcinoma, 32 non-small cell carcinoma NOS, and 6 other (carcinosarcoma, giant cell carcinoma).
  • The assessment of NE differentiation in NSCLC is unnecessary and expensive and is of no clinical or prognostic significance.
  • SNP is more likely to be expressed in adenocarcinoma (P=0.01) and N-CAM in squamous-cell carcinoma (P=0.008).
  • Disease specific and overall survival is not influenced by NE differentiation and therefore non-small cell lung carcinoma with neuroendocrine differentiation should not be a subclass distinct from the other NSCLC.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197916.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranins; 0 / Neural Cell Adhesion Molecules; 0 / Synaptophysin
  •  go-up   go-down


7. Kitamoto K, Hayashi T, Tamada S, Ezaki K, Kawashima H, Sugimura K, Nakatani T: [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report]. Hinyokika Kiyo; 2005 Jan;51(1):33-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
  • Prostatic neuroendocrine (NE) carcinoma is a rare disease with a poor prognosis because of its rapid progression and the androgen-independent characteristic, for which no successful therapy is available presently.
  • We report a case of NE differentiated prostate cancer, which was diagnosed as adenocarcinoma initially and progressed with NE differentiation during the combined androgen blockade therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Androgen Antagonists / therapeutic use. Carcinoma, Neuroendocrine / pathology. Cell Transformation, Neoplastic / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732339.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


8. Tamas EF, Epstein JI: Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate. Am J Surg Pathol; 2006 Aug;30(8):980-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate.
  • The prognostic significance of Paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate has not yet been established.
  • We studied 36 cases of adenocarcinoma of the prostate showing Paneth cell-like neuroendocrine differentiation, including needle biopsy specimens (n = 27), radical prostatectomies (n = 8), and transurethral resection specimens (n = 1).
  • Paneth cell-like neuroendocrine cells (NECs) were observed as either patchy isolated cells or diffusely involving glands or nests.
  • Of the 16 radical prostatectomy cases, 8 (50%) had a Gleason pattern 5 component either on needle biopsy or at radical prostatectomy, with nests, cords, or single cells containing Paneth cell-like neuroendocrine differentiation.
  • Despite the cells' bland histologic appearance, strictly applying the Gleason grading system one would have to assign a Gleason pattern 5 to these foci with no glandular differentiation.
  • In cases with Paneth cell-like NECs, only the conventional adenocarcinoma component should be assigned a Gleason score.
  • In cases in which the entire tumor is composed of Paneth cell-like cells and areas of the tumor lack glandular differentiation, the tumors should not be assigned a Gleason score and a comment should be provided as to the generally favorable prognosis of this morphologic pattern of neuroendocrine differentiation.
  • [MeSH-major] Adenocarcinoma / pathology. Paneth Cells / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861969.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Sagnak L, Topaloglu H, Gucuk O, Han U, Ersoy H: Skip metastase on the left neck lymph nodes of the prostatic adenocarcinoma with neuroendocrine differentiation and accompanying thyroid micropapillary carcinoma. Pathol Oncol Res; 2008 Dec;14(4):493-5
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skip metastase on the left neck lymph nodes of the prostatic adenocarcinoma with neuroendocrine differentiation and accompanying thyroid micropapillary carcinoma.
  • We discuss here the thyroid micropapillary carcinoma that was detected incidentally when investigating the primary focus of the left neck multiple lymph node metastases occurring 8 months later in a patient of ours, whose pathological examination of radical prostatectomy and bilateral inguinal lymph node dissection was reported to be pT3N0 and whole body scanning for metastases, was negative.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Papillary / pathology. Lymphatic Metastasis / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Cell Differentiation. Humans. Incidental Findings. Lymph Nodes / pathology. Male. Middle Aged. Neck / pathology. Nitriles / therapeutic use. Orchiectomy. Prostate-Specific Antigen / blood. Prostatectomy. Thyroidectomy. Tosyl Compounds / therapeutic use. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386164.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


10. Pozo L, Diaz-Cano SJ: Trichilemmal carcinoma with neuroendocrine differentiation. Clin Exp Dermatol; 2008 Mar;33(2):128-31
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichilemmal carcinoma with neuroendocrine differentiation.
  • To our knowledge, this is the first documented case of a trichilemmal carcinoma with neuroendocrine differentiation and melanocyte colonization, which is suggested by the trabecular growth pattern and requires immunohistochemical confirmation.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Skin Appendage / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Male. Melanocytes / pathology. Phenotype

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076695.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Xiao WL, Zhou FT, Feng YY, Li NY: Submandibular area metastasis from prostate small cell carcinoma with neuroendocrine differentiation. J Craniofac Surg; 2007 Sep;18(5):1155-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Submandibular area metastasis from prostate small cell carcinoma with neuroendocrine differentiation.
  • Neuroendocrine differentiation in prostatic carcinomas generally confers a more aggressive clinical behavior and less favorable prognosis than usual prostatic carcinomas.
  • In this article, we report a case of a 65-year-old man with prostatic carcinoma who had a metastasis of the submandibular area.
  • Pathologic specimens demonstrated a small cell carcinoma with neuroendocrine differentiation by immunohistochemical studies.
  • [MeSH-major] Carcinoma, Small Cell / secondary. Prostatic Neoplasms / pathology. Submandibular Gland Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17912103.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Parada DD, Peña KB: Chromophobe renal cell carcinoma with neuroendocrine differentiation. APMIS; 2008 Sep;116(9):859-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromophobe renal cell carcinoma with neuroendocrine differentiation.
  • Chromophobe renal cell carcinoma was described by Thoenes et al. in 1986, and associations with carcinoma of collecting ducts, conventional renal cell carcinoma and sarcomatoid renal cell carcinoma have been described.
  • We report a case of chromophobe renal cell carcinoma which showed neuroendocrine differentiation.
  • The tumor showed a mixture of classical and eosinophilic patterns of chromophobe cell carcinoma.
  • Immunohistochemically, the neuroendocrine areas were reactive for C-kit, epithelial membrane antigen, cytokeratin, cytokeratin 7, chromogranin A, neuron-specific enolase, CD56 and S-100 protein.
  • Our case represents a typical chromophobe carcinoma with neuroendocrine differentiation.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Cell Differentiation / physiology. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Middle Aged


13. Kuroda N, Oonishi K, Iwamura S, Ohara M, Hirouchi T, Mizumo K, Miyazaki E, Enzan H: Gastric carcinosarcoma with neuroendocrine differentiation as the carcinoma component and leiomyosarcomatous and myofibroblastic differentiation as the sarcomatous component. APMIS; 2006 Mar;114(3):234-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric carcinosarcoma with neuroendocrine differentiation as the carcinoma component and leiomyosarcomatous and myofibroblastic differentiation as the sarcomatous component.
  • Gastric carcinosarcoma with neuroendocrine differentiation is a very rare neoplasm.
  • The tumor was composed of carcinoma and sarcomatous cells, and the histological transition of both components was observed.
  • Immunohistochemically, carcinoma and sarcomatous cells were positive for cytokeratin CAM5.2.
  • The carcinoma contained adenocarcinoma and malignant cells with neuroendocrine differentiation.
  • The sarcomatous component showed leiomyosarcomatous and myofibroblastic differentiation.
  • The present tumor is the fifth case of gastric carcinosarcoma with neuroendocrine differentiation and the first case of gastric carcinosarcoma with myofibroblastic differentiation.
  • Pathologists should bear in mind that gastric carcinosarcoma may show various types of differentiation.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinosarcoma / pathology. Cell Differentiation. Leiomyosarcoma / pathology. Neoplasms, Muscle Tissue / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643190.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


14. Fiorito C, Lucca I, Oderda M, Mondino P, Berta G, Cattaneo EA, Valentino F, Zitella A, Pacchioni D: [Neuroendocrine bladder cancer: oncological emergency?]. Urologia; 2008 Jan-Mar;75(1):57-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine bladder cancer: oncological emergency?].
  • Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.5%- 0.7%.
  • In bladder cancers there is no evident connection between the neuroendocrine phenotypic expression and the clinical history.
  • METHODS. We are here describing three case reports of bladder carcinoma with neuroendocrine differentiation, which is extremely aggressive and leads rapidly to death.
  • CONCLUSIONS. Considering the quick evolution and progression of any variant of the neuroendocrine tumors of the bladder, urologists and anesthetists should see them as real oncological emergencies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086378.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Roy S, Dhingra KK, Gupta P, Khurana N, Gupta B, Meher R: Acinic cell carcinoma with extensive neuroendocrine differentiation: a diagnostic challenge. Head Neck Pathol; 2009 Jun;3(2):163-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma with extensive neuroendocrine differentiation: a diagnostic challenge.
  • Primary salivary gland carcinoma with neuroendocrine differentiation is of rare occurrence, especially so in the parotid gland.
  • Amongst the various reported primary tumors with neuroendocrine differentiation, acinic cell carcinoma (ACC) one such tumor.
  • Contrast Enhanced Computed Tomography (CECT) suggested diagnosis of Pleomorphic Adenoma.
  • Initial histopathological examination of the tumor was suggestive of neuroendocrine carcinoma.
  • Immunoexpression of S-100, Neuron specific Enolase (NSE), Chromogranin A and Synaptophysin confirmed the diagnosis.
  • The possibility of neuroendocrine differentiation in a primary salivary gland tumor should be kept in mind whenever a salivary gland tumor shows only neuroendocrine histology.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adenolymphoma / pathology. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathobiology. 1990;58(4):212-20 [1701303.001]
  • [Cites] Ear Nose Throat J. 2006 Aug;85(8):533-9 [16999063.001]
  • [Cites] APMIS. 2006 Oct;114(10):720-5 [17004975.001]
  • [Cites] Pancreas. 2009 Mar;38(2):219-22 [19238022.001]
  • [Cites] Mod Pathol. 2000 May;13(5):554-61 [10824928.001]
  • [Cites] Acta Pathol Jpn. 1990 Apr;40(4):279-87 [2371833.001]
  • [Cites] Am J Otolaryngol. 2004 Mar-Apr;25(2):129-33 [14976661.001]
  • [Cites] J Laryngol Otol. 1979 Apr;93(4):325-40 [438614.001]
  • [Cites] J Clin Pathol. 1982 Jun;35(6):611-6 [7085912.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):962-8 [3300954.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1583-8 [2441846.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3C):2131-4 [11501836.001]
  • (PMID = 19644544.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acinic cell / Carcinoma / Chromogranin / Neuroendocrine / Parotid / Warthin’s
  •  go-up   go-down


16. Volante M, Righi L, Asioli S, Bussolati G, Papotti M: Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms. Virchows Arch; 2007 Aug;451 Suppl 1:S61-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms.
  • Within the spectrum of neuroendocrine tumors arising in different organs, intermediate and controversial entities exist displaying a coexistence of neuroendocrine and nonneuroendocrine cell populations, and that are grouped under terms such as "goblet cell carcinoid", "mixed endocrine-exocrine carcinoma", "combined carcinomas", or "adenocarcinoma with neuroendocrine differentiation".
  • These tumors may display variable amounts of the two components, potentially ranging from 1 to 99%, and variable structural patterns, ranging from single scattered neuroendocrine cells to a well-defined neuroendocrine tumor cell component organized in typical organoid, trabecular, or solid growth patterns.
  • In the present report, the main characteristics of tumors showing mixed neuroendocrine and nonneuroendocrine features will be described, using morphological patterns and site of origin as schematic guidelines.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684764.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 77
  •  go-up   go-down


17. Sharifzadeh S, Modjtahedi H, Jedi Tehrani M, Bayat A, Ghaderi A: Production and characterization of a monoclonal antibody against an antigen on the surface of non-small cell carcinoma of the lung. Iran J Immunol; 2007 Dec;4(4):206-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Production and characterization of a monoclonal antibody against an antigen on the surface of non-small cell carcinoma of the lung.
  • BACKGROUND: Lung carcinoma is a multiple type cancer comprising of small cell and non-small cell carcinomas (NSCLC).
  • METHODS: A murine monoclonal antibody (ME3D11) reactive with human NSCLC was selected after immunization of BALB/c mice with a human large cell carcinoma with neuroendocrine differentiation, and was tested by immunofloursence staining and Western blot analysis.
  • This antigen is expressed on the cell surface of all NSCLC and a few carcinoma cell lines.
  • CONCLUSIONS: High degree of binding of this monoclonal antibody to NSCLC and some other carcinoma cells warrants further studies on its potential use in diagnosis and therapy of cancer by conjugation to drugs, toxins or radionuclides.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / metabolism. Antigens, Neoplasm / immunology. Carcinoma, Non-Small-Cell Lung / immunology. Lung Neoplasms / immunology. Membrane Proteins / immunology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057578.001).
  • [ISSN] 1735-1383
  • [Journal-full-title] Iranian journal of immunology : IJI
  • [ISO-abbreviation] Iran J Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Membrane Proteins
  •  go-up   go-down


18. Jiang SX, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I: Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol; 2006 Aug;30(8):945-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity.
  • The current histologic classifications of gastric cancers define only carcinoids and small cell carcinomas in the neuroendocrine (NE) category.
  • This study aimed to characterize the histologic and clinical features of high-grade gastric NE carcinomas of nonsmall cell type, tentatively named large cell neuroendocrine carcinoma (LCNEC).
  • Tumors with histologic features suspicious of NE differentiation were selected by a histologic review of 2835 resected gastric cancers, and those with a NE phenotype in > 50% and 1% to approximately 50% tumor cells assessed by expressing chromogranin A and/or synaptophysin were defined as LCNEC and adenocarcinoma with neuroendocrine differentiation (ACNED), respectively.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Chromogranin A. Chromogranins / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Prognosis. Survival Analysis. Survival Rate. Synaptophysin / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861964.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 0 / Synaptophysin
  •  go-up   go-down


19. Kontic M, Stojsic J, Kacar-Kukric V, Jekic B, Bunjevacki V: Multidisciplinary approach in diagnosis of lung carcinoma. Exp Oncol; 2010 Jul;32(2):111-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary approach in diagnosis of lung carcinoma.
  • AIM: To employ multidisciplinary approach in order to make the correct diagnosis of lung carcinoma clinically and morphologically mimicking lymphoma.
  • Further, tumor cells expressed neuroendocrine mar kers: synaptophysin, chromogranin A, neuron-specific enolase (NSE), CD56/NCAM, CD57/Leu-7 and protein gene product 9.5 (PGP9.5).
  • Final diagnosis of large cell lung neuroendocrine carcinoma (LCNEC) was established.
  • CONCLUSIONS: Morphological pattern of tumor complied with large cell non-Hodgkin's lymphoma, but large cell lung carcinoma with neuroendocrine differentiation was proved immunohistochemically and confirmed by genetic analysis of p53 mutations in tumor tissue sample.
  • Multidisciplinary approach in diagnosis of lung carcinoma is useful for its final diagnosis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Large Cell / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Base Sequence. Diagnosis, Differential. Humans. Immunohistochemistry. Lymphoma / pathology. Male. Middle Aged. Molecular Sequence Data. Mutation. Polymerase Chain Reaction. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20693974.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


20. Molenaar JP, Baten A, Blokx WA, Hoogendam A: Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate. Eur Urol; 2009 Nov;56(5):874-7; quiz 876
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
  • We present the case of an 81-yr-old man with a prostatic adenocarcinoma and a metastatic carcinoid.
  • Simultaneous occurrence of hormonally treated adenocarcinoma of the prostate and a carcinoid has been described before.
  • The pathogenesis of this coincidence is largely unclear; however, androgen deprivation therapy might play a key role in neuroendocrine differentiation of adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19171417.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; 51110-01-1 / Somatostatin; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


21. Kumaki N, Umemura S, Kajiwara H, Itoh J, Itoh Y, Osamura RY: Immunohistochemical analysis of neuroendocrine (NE) differentiation in testicular germ cell tumors (GCTs): use of confocal laser scanning microscopy (CLSM) to demonstrate direct NE differentiation from GCTs. Acta Histochem Cytochem; 2007 Dec 21;40(6):143-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of neuroendocrine (NE) differentiation in testicular germ cell tumors (GCTs): use of confocal laser scanning microscopy (CLSM) to demonstrate direct NE differentiation from GCTs.
  • Neuroendocrine (NE) differentiation is infrequent in testicular tumors and its histogenesis is not well understood.
  • The present study is aimed at elucidating the pathway of neuroendocrine differentiation in germ cell tumors (GCTs) of the testis.
  • In the analysis of 46 germ cell tumor components from 23 testicular tumors, we focused on GCTs with neuroendocrine differentiation, 7 teratoma, 1 embryonal carcinoma and 1 neuroendocrine carcinoma by immunohistochemical study and confocal laser scanning microscopy (CLSM) analysis.
  • NE marker positive cells were noted in the tumor with collision of teratoma and embryonal carcinoma (E&T tumor), in the immature columnar cells of transitional form of embryonal carcinoma to teratoma (E-T cells) and neuroendocrine carcinoma cells, in addition to the well known mature intestinal mucosa in teratoma.
  • Another finding, indicating the intimate relation between embryonal carcinoma and neuroendocrine differentiation, is that neuroendocrine carcinoma expressed a marker of embryonal carcinoma, CD30.
  • The present results indicated that the NE cells might be differentiated from embryonal carcinoma, a view that has not been proposed before, but that is made in the present study using CLSM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Reprod. 2003 Aug;69(2):612-6 [12700182.001]
  • [Cites] Cancer. 1975 Aug;36(2):404-18 [1157010.001]
  • [Cites] Pol J Pathol. 1996;47(2):91-3 [8854733.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1726-32 [7688660.001]
  • [Cites] Am J Clin Pathol. 1982 Dec;78(6):860-4 [6183972.001]
  • [Cites] J Histochem Cytochem. 1968 Sep;16(9):557-60 [5717715.001]
  • [Cites] Am J Clin Pathol. 2003 Aug;120(2):182-7 [12931547.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):446-50 [2849300.001]
  • [Cites] Toxicol Pathol. 1989;17(2):307-16 [2675281.001]
  • [Cites] J Histochem Cytochem. 2007 May;55(5):487-93 [17242462.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):866-83 [17125591.001]
  • [Cites] Cell. 2004 Dec 29;119(7):1001-12 [15620358.001]
  • [Cites] Cancer. 1978 Dec;42(6):2696-706 [365317.001]
  • (PMID = 18224246.001).
  • [ISSN] 0044-5991
  • [Journal-full-title] Acta histochemica et cytochemica
  • [ISO-abbreviation] Acta Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2156079
  • [Keywords] NOTNLM ; confocal laser scanning microscopy (CLSM) / embryonal carcinoma / germ cell tumor / neuroendocrine cell / testis
  •  go-up   go-down


22. Turbat-Herrera EA, Herrera GA: Electron microscopy renders the diagnostic capabilities of cytopathology more precise: an approach to everyday practice. Ultrastruct Pathol; 2005 Nov-Dec;29(6):475-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By the use of EM the authors can make specific final diagnoses, make the diagnosis more definitive, narrow the differential diagnosis, or determine the origin of a neoplasm with unknown primary site.
  • The common diagnostic dilemmas in the everyday practice of cytology are the following: mesothelioma vs. adenocarcinoma, neuroendocrine differentiation or not, the distinction of melanoma from adenocarcinoma and sarcoma, hepatocellular carcinoma vs. adenocarcinoma, and the origin of adenocarcinomas of unknown primary.
  • [MeSH-major] Microscopy, Electron, Transmission. Neoplasms / diagnosis. Neoplasms / ultrastructure
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Biopsy, Fine-Needle. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Liver Neoplasms / diagnosis. Male. Melanoma / diagnosis. Mesothelioma / diagnosis. Sarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16316948.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


23. Tang Y, Wang L, Goloubeva O, Khan MA, Lee D, Hussain A: The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice. Prostate; 2009 Dec 1;69(16):1763-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice.
  • BACKGROUND: Neuroendocrine differentiation and neuroendocrine carcinoma (NEC) have been linked to androgen deprivation in prostate cancers.
  • No previous study has directly connected neuroendocrine phenotypes to chemotherapy.
  • METHODS: Using the transgenic adenocarcinoma of mouse prostate (TRAMP) model, we studied tumor progression after hormone ablation (castration) and/or chemotherapy (docetaxel), and analyzed the incidence of NEC as a function of the anti-tumor therapies.
  • The NEC-bearing mice had smaller tumors in their prostates and lived longer than mice with adenocarcinoma (ADC-only).
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Neuroendocrine / chemically induced. Prostatic Neoplasms / drug therapy. Taxoids / adverse effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19691128.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Androgen Antagonists; 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


24. Leja J, Essaghir A, Essand M, Wester K, Oberg K, Tötterman TH, Lloyd R, Vasmatzis G, Demoulin JB, Giandomenico V: Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol; 2009 Feb;22(2):261-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas.
  • The gene expression profile of metastasizing serotonin-producing neuroendocrine carcinomas, which arise from enterochromaffin cells in the jejunum and ileum, is still largely unknown.
  • The aim of this study was to identify genes and proteins, which are preferentially expressed by neuroendocrine carcinoma and enterochromaffin cells and therefore potential novel biomarkers and/or therapeutic targets.
  • Six carcinoma specimens and six normal ileal mucosas were profiled by Affymetrix microarrays.
  • We identified six novel marker genes for neuroendocrine carcinoma cells: paraneoplastic antigen Ma2 (PNMA2), testican-1 precursor (SPOCK1), serpin A10 (SERPINA10), glutamate receptor ionotropic AMPA 2 (GRIA2), G protein-coupled receptor 112 (GPR112) and olfactory receptor family 51 subfamily E member 1 (OR51E1).
  • GRIA2 is specifically expressed by neuroendocrine carcinoma cells whereas the others are also expressed by normal enterochromaffin cells.
  • GPR112 and OR51E1 encode proteins associated with the plasma membrane and may therefore become targets for antibody-based diagnosis and therapy.
  • However, chemokine C-X-C motif ligand 14 (CXCL14) and NK2 transcription factor related locus 3 Drosophila (NKX2-3) are expressed to a lower level in liver metastases than in primary tumors and normal enterochromaffin cells, which implies a role in neuroendocrine carcinoma differentiation.
  • In conclusion, this study provides a list of genes, which possess relatively specific expression to enterochromaffin and neuroendocrine carcinoma cells and genes with differential expression between primary tumors and metastases.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Neuroendocrine / genetics. Enterochromaffin Cells / chemistry. Gene Expression Regulation, Neoplastic. Ileal Neoplasms / genetics. Ileum / chemistry. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - ADGRG4 - data and references .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953328.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


25. Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS: Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol; 2010 Sep;23(9):1180-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation.
  • Fibrolamellar carcinoma is a rare malignant primary liver neoplasm with characteristic histological features that typically arises in young patients without viral hepatitis or cirrhosis.
  • In contrast to classical hepatocellular carcinoma, individual cases of fibrolamellar carcinoma have been reported to express cytokeratin 7.
  • In addition, ultrastructural and serological studies have suggested that fibrolamellar carcinoma may show neuroendocrine differentiation.
  • The cellular differentiation of fibrolamellar carcinoma has not been studied and little is reported about its immunohistochemical profile.
  • We studied 26 cases of fibrolamellar carcinoma and 62 cases of classical hepatocellular carcinoma by immunohistochemistry for HepPar1, glypican-3, pCEA, CD10, alpha-fetoprotein, cytokeratin 20, neuroendocrine markers, and surrogate markers for biliary differentiation (cytokeratin 7, cytokeratin 19, epithelial membrane antigen, EpCAM, mCEA, B72.3, and CA19.9).
  • Tumor cells of fibrolamellar carcinoma and hepatocellular carcinoma showed positive signals for albumin mRNA by in situ hybridization in all cases.
  • Both tumor types stained uniformly positively with HepPar1 and most showed a canalicular staining pattern for pCEA, confirming their hepatocellular differentiation.
  • In addition, 39% of hepatocellular carcinoma cases and 59% of fibrolamellar carcinoma cases were positive for glypican-3.
  • All 22 fibrolamellar carcinoma cases tested showed positive staining for cytokeratin 7 and epithelial membrane antigen, whereas less than one-third of hepatocellular carcinoma cases were positive for these markers (P<0.0001).
  • Further, 36% of fibrolamellar carcinoma cases showed staining for B72.3, cytokeratin 19, EpCAM, or mCEA.
  • Minimal evidence of neuroendocrine differentiation in either tumor was found with any of the usual immunohistochemical markers used for this purpose.
  • Therefore, cytokeratin 7 and epithelial membrane antigen may be useful to differentiate between fibrolamellar carcinoma and hepatocellular carcinoma.
  • On the basis of immunohistochemistry, fibrolamellar carcinoma seems to show both hepatocellular and bile duct differentiation.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Differentiation. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Tissue Array Analysis

  • Genetic Alliance. consumer health - Fibrolamellar carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495535.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Fibrolamellar hepatocellular carcinoma
  •  go-up   go-down


26. Krokowski M, Hoch J, Feller AC, Bernd HW, Thorns C, Krueger S: Basal cell carcinoma with neuroendocrine differentiation arising in a scar: A case report. Dermatol Online J; 2009;15(10):4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with neuroendocrine differentiation arising in a scar: A case report.
  • Basal cell carcinoma (BCC), the most common cutaneous malignant tumor, may display neuroendocrine differentiation in very rare instances.
  • We here describe a case of a BCC with neuroendocrine differentiation that arose in a scar resulting from a trauma 75 years earlier.
  • Neuroendocrine differentiation was proven by immunohistochemistry and electron microscopy.
  • The simultaneous occurrence of BCC development in a scar and neuroendocrine differentiation is quite rare.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Cicatrix / complications. Skin Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951622.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Pacchioni D, Bosco M, Allia E, Mussa B, Mikuz G, Bussolati G: Microcystic urothelial cell carcinoma with neuroendocrine differentiation arising in renal pelvis. Report of a case. Virchows Arch; 2009 Feb;454(2):223-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic urothelial cell carcinoma with neuroendocrine differentiation arising in renal pelvis. Report of a case.
  • Microcystic urothelial cell carcinoma is a rare variant of urothelial cell carcinoma which occurs in the bladder and, rarely, in the renal pelvis.
  • Neuroendocrine differentiation is uncommon in pure urothelial carcinoma and is more frequently found in neoplasms with glandular differentiation.
  • We report a case of microcystic urothelial cell carcinoma arising in renal pelvis and showing focal neuroendocrine differentiation.
  • Microscopic examination disclosed invasive carcinoma with prominent microcystic features, with microcysts lined by low columnar and flat cells.
  • Immunohistochemical analysis confirmed the urothelial histotype (positive for thrombomodulin, p63 and high-molecular-weight cytokeratins) and disclosed focal neuroendocrine differentiation.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Kidney Neoplasms / pathology. Kidney Pelvis / pathology
  • [MeSH-minor] Cell Differentiation. Humans. Immunohistochemistry. Male. Middle Aged. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19002493.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Emanuel PO, de Vinck D, Waldorf HA, Phelps RG: Recurrent endocrine mucin-producing sweat gland carcinoma. Ann Diagn Pathol; 2007 Dec;11(6):448-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endocrine mucin-producing sweat gland carcinoma.
  • Endocrine mucin-producing sweat gland carcinoma is a rare skin tumor that most commonly involves the eyelid of elderly women.
  • Morphologically and immunohistochemically, it is analogous to endocrine ductal carcinoma in situ of the breast and mammary solid papillary carcinoma; also, like the analogous breast lesion, there is an often associated invasive mucinous carcinoma with neuroendocrine differentiation.
  • We describe the case of a 65-year-old woman with endocrine mucin-producing sweat gland carcinoma of the eyelid that recurred 3 years after an apparently complete excision.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Eyelid Neoplasms / pathology. Mucins / biosynthesis. Neoplasm Recurrence, Local / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022131.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


29. Pratz KW, Ma C, Aubry MC, Vrtiska TJ, Erlichman C: Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome. Mayo Clin Proc; 2005 Jan;80(1):116-20
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome.
  • We describe a 38-year-old man with metastatic non-small cell lung cancer of large cell carcinoma with neuroendocrine differentiation who presented with bone metastasis and intractable secretory diarrhea that was unresponsive to pharmacological treatment, including octreotide.
  • Chemotherapy resulted in a transient response in the patient's diarrhea and neuroendocrine markers.
  • To our knowledge, this is the first published case of large cell carcinoma with neuroendocrine differentiation associated with treatment-responsive paraneoplastic Verner-Morrison syndrome.
  • [MeSH-major] Calcitonin / secretion. Carcinoma, Large Cell / secretion. Lung Neoplasms / secretion. Pancreatic Neoplasms / etiology. Paraneoplastic Endocrine Syndromes / etiology. Vasoactive Intestinal Peptide / metabolism. Vipoma / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667039.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 37221-79-7 / Vasoactive Intestinal Peptide; 9007-12-9 / Calcitonin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


30. Yamamoto N, Kinoshita H, Inoue T, Kawakita S, Oguchi N, Muguruma K, Kawa G, Sakaguchi Y, Adachi Y, Sakaida N, Uemura Y, Matsuda T: [Small cell carcinoma of the prostate: a case report]. Hinyokika Kiyo; 2007 Sep;53(9):665-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of the prostate: a case report].
  • A 76-year-old man had been treated with maximum androgen blockade therapy for a poorly-differentiated prostate adenocarcinoma (T3cN1M0, prostate specific antigen (PSA) 65 ng/ml, Gleason Score 4+5=9) since September 2002.
  • Immunohistochemical examination of a biopsy specimen from the bone lesion revealed a small cell carcinoma/neuroendocrine cell carcinoma.
  • The immunohistochemical examination revealed pure small cell carcinoma in all metastatic lesions.
  • We concluded from the clinical history and autopsy findings that his initial poorly-differentiated adenocarcinoma of the prostate dedifferentiated into a pure small cell carcinoma with neuroendocrine differentiation.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Cell Transformation, Neoplastic. Humans. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933147.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down


31. Ding HY, Gao LX: [Spindle cell carcinoma of breast with neuroendocrine differentiation]. Zhonghua Bing Li Xue Za Zhi; 2006 Jan;35(1):13-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spindle cell carcinoma of breast with neuroendocrine differentiation].
  • OBJECTIVE: To describe the morphologic features and immunohistochemistry of spindle cell carcinoma of breast with neuroendocrine differentiation.
  • METHODS: Retrospective review of 2500 cases of breast carcinoma showed 5 cases (0.2%) with a predominance (> 80%) of spindle cell component.
  • Amongst the 5 cases studied, 2 represented intraductal spindle cell carcinoma and 3 represented invasive spindle cell carcinoma.
  • Two cases of intraductal spindle cell carcinoma and 1 of the 3 cases of invasive spindle cell carcinoma were classified as neuroendocrine carcinoma of spindle cell type, while the remaining 2 cases of invasive spindle cell carcinoma were considered as metaplastic carcinoma with neuroendocrine differentiation.
  • Amongst the 4 patients with follow-up information available, 3 were still alive 24 to 58 months after the initial diagnosis.
  • One patient died within 27 months of diagnosis.
  • CONCLUSIONS: The presence of spindle tumor cells and sometimes intracytoplasmic mucin are useful morphologic clues in diagnosing spindle cell carcinoma of the breast with neuroendocrine differentiation.
  • Intraductal neuroendocrine spindle cell carcinoma needs to be distinguished from usual ductal hyperplasia and intraductal papilloma.
  • On the other hand, invasive spindle cell carcinoma with neuroendocrine differentiation needs to be distinguished from spindle cell myoepithelioma, malignant melanoma and sometimes soft tissue neoplasm.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Neuroendocrine Tumors / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Chromogranin A. Chromogranins / analysis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged. Phosphopyruvate Hydratase / analysis. Retrospective Studies. Synaptophysin / analysis


32. Meeks JJ, Habermacher GM, Le B, Smith ND: Delayed diagnosis of prostate cancer with neuroendocrine differentiation after laser TURP. Urology; 2008 Oct;72(4):948.e11-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed diagnosis of prostate cancer with neuroendocrine differentiation after laser TURP.
  • The patient subsequently underwent bipolar TURP, and the pathologic examination of the prostate chips revealed highly aggressive prostate adenocarcinoma with neuroendocrine differentiation.
  • We discuss the potential drawbacks of laser TURP in the diagnosis of clinically undetectable prostate cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / surgery. Transurethral Resection of Prostate
  • [MeSH-minor] Carcinoma, Neuroendocrine / pathology. Humans. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342929.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Li N, Wolgamot G, Argenyi Z: Primary cutaneous neuroendocrine cell carcinoma (Merkel cell carcinoma) with prominent microcystic features, mimicking eccrine carcinoma. J Cutan Pathol; 2007 May;34(5):410-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous neuroendocrine cell carcinoma (Merkel cell carcinoma) with prominent microcystic features, mimicking eccrine carcinoma.
  • Although primary cutaneous neuroendocrine cell carcinoma [Merkel cell carcinoma (MCC)] may show divergent features, including microcystic ('tubuloglandular'), squamous, eccrine and rhabdomyoblastic, a diffuse microcystic pattern is exceedingly rare.
  • In this study, we present two cases of MCC with prominent microcystic features, which precluded a definitive diagnosis in the initial punch biopsy.
  • Although the lack of CK20 staining is unusual, the histologic characteristics along with the remaining immunohistochemical studies favor the diagnosis of a primary cutaneous neuroendocrine cell carcinoma over the variants of eccrine carcinoma or basal cell carcinoma with neuroendocrine differentiation.
  • Our cases illustrate that prominent microcystic features, mimicking glandular differentiation, may occur in MCC and pose a diagnostic challenge in small biopsy specimens.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Eccrine Glands / pathology. Humans. Immunohistochemistry. Male. Neck / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448197.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


34. Kitakata H, Yasumoto K, Sudo Y, Minato H, Takahashi Y: A case of primary small cell carcinoma of the breast. Breast Cancer; 2007;14(4):414-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary small cell carcinoma of the breast.
  • We report a rare case of primary small cell carcinoma of the breast.
  • Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung.
  • The tumor cells were positive for neuroendocrine differentiation markers such as synaptophysin, CD56, and neuron-specific enolase (NSE), but negative for thyroid transcription factor-1 (TTF-1), leukocyte common antigen (LCA), estrogen receptor (ER), and progesterone receptor (PR).
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986808.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down






Advertisement